Tag Archives: science

BioMetas and ZSHK Laboratories Announce Strategic Integration to Build a Full Preclinical CRO Platform

14 Apr

Life Science Nation (LSN) is pleased to highlight an important development from one of our long term partners. BioMetas, Title Sponsor of the RESI conferences in 2026, has announced a strategic integration with ZSHK Laboratories to build a comprehensive preclinical drug discovery and development CRO platform.

This move reflects a continued push toward greater integration across the early stages of drug development, an area where fragmentation has historically slowed progress for emerging companies.

On April 13, 2026, BioMetas Group and ZSHK Laboratories formally completed a strategic integration at BioMetas’ Shanghai headquarters. The signing ceremony included leadership from both organizations as well as representatives from key shareholders, including CFS Capital, Huagai Capital, Qiming Venture Partners, ACM Capital, and the AstraZeneca CICC Fund.

BioMetas has grown rapidly over the past four years as a globally oriented preclinical CRO, with approximately 85 percent of its revenue generated from international clients. The company has developed core capabilities across early research, including protein science, in vitro and in vivo efficacy evaluation, and DMPK, with particular strength in oncology and autoimmune disease programs.

ZSHK Laboratories brings a complementary set of capabilities centered on GLP toxicology services. The company operates internationally certified GLP facilities in Suzhou and Shenzhen and maintains dedicated animal research infrastructure, including non human primate and canine models. Its services span pharmacokinetics, toxicology, and safety evaluation, with a client base primarily concentrated in the domestic Chinese market.

Following the integration, the combined platform is designed to provide a continuous, end to end preclinical development pathway. The service model spans early research, including target validation, molecular screening, and efficacy studies; translational work, including DMPK and dose exploration; and regulatory support, including GLP safety evaluation, toxicology, and safety pharmacology. By consolidating these capabilities within a single platform, the integrated organization aims to reduce handoff between service providers, improve data consistency, and accelerate timelines toward IND.

The integration also strengthens access to experimental animal resources and expands model coverage across multiple species and disease areas, supporting more complex mechanism studies and advanced preclinical programs.

From a strategic standpoint, the companies have indicated a focus on building a broader service plus capital ecosystem, combining scientific capability, operational scale, and capital market alignment to enhance global competitiveness. The transaction reflects a broader trend within the CRO industry toward platform integration, moving beyond cost driven specialization toward more comprehensive, value oriented service models.

For early stage drug development companies, the implication is clear: an integrated preclinical pathway reduces friction, accelerates timelines, and creates a more coherent progression from discovery through IND enabling studies. With this integration, BioMetas strengthens its ability to deliver fast, cost-efficient, high-quality services within a comprehensive platform, positioning itself as a valuable partner for both domestic Chinese innovation and global programs. This combination of speed, efficiency, and execution quality highlights the growing role of leading platforms like BioMetas in moving China further into the forefront of the global early stage drug development landscape.

Tags: , , , , , , , , , , , , , , ,

From Proof to Approval: Regulatory Risk 

14 Apr

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022

As part of Life Science Nation’s series on converting scientific innovation into investable signal, the focus now moves to the next layer of the De-Risk Stack. In the previous article, technical risk addressed whether a product works and can be trusted. The next question is whether it can realistically be approved.

This article examines regulatory risk, where feasibility must become predictability. It outlines how companies define a clear path to approval—covering regulatory pathways, precedent, endpoint selection, trial design, and engagement with regulators.

From aligning with evidence requirements to understanding timelines and cost, this piece breaks down what it takes to move from promising data to an executable plan that investors can underwrite.

Regulatory Risk 

From Feasibility to Predictability

Once the product works, the next question is whether it can be approved.

Regulatory risk is often underestimated because it is treated as an after-the-fact compliance requirement instead of a primary design constraint. In reality, it defines timelines, capital requirements, and feasibility. Without a credible path, investment becomes difficult regardless of how strong the data may be.

The core issue is predictability. Investors need to understand not just that approval is possible, but how it will be achieved, how long it will take, and what it will cost.

This begins with pathway clarity. The regulatory route must be defined early—whether the asset is headed toward an IND and NDA/BLA, a 510(k), a PMA, or another pathway. Precedent provides context by showing how similar products, mechanisms, or indications have been evaluated. Without precedent, uncertainty and perceived risk rise sharply.

Endpoints and trial design then determine whether the plan is executable. Success must be measurable in a way regulators accept, and the required studies must be feasible in terms of recruitment, duration, complexity, and cost. A theoretically elegant trial that cannot be run in the real world is equivalent to having no trial plan at all.

Regulatory interaction further refines the path. Pre-IND or pre-submission meetings align expectations, clarify requirements, and reduce unnecessary iteration. Proceeding without this engagement increases risk and can lead to expensive rework.

Safety requirements, timeline expectations, and the cost of approval define the remaining boundaries. Each indication and modality carries a different tolerance for risk and a different evidence bar, and each pathway implies a specific capital profile.

Regulatory risk is resolved when the path to approval is defined, evidence requirements are understood, and the plan is both credible and executable within known time and capital constraints.

Core Elements of Regulatory Risk 

  • Pathway clarity
  • Precedent
  • Endpoint definition
  • Trial design feasibility
  • Regulatory interaction
  • Safety requirements
  • Timeline predictability
  • Cost of approval

Next in the series: Execution Risk — Turning Plan into Progress 

Previous Articles：

Technical Risk – From Belief to Evidence

The Problem Is Not the Science: A Seven-Part Series on De-Risking, Signal, and Investability

Tags: , , , , , , , , , , , , , , ,

Innovator’s Pitch Challenge Winner Spotlight: Bram De Moor of You2Yourself 

14 Apr

Following its recognition as a winner of the Innovator’s Pitch Challenge at RESI Europe, You2Yourself is advancing a new approach to early disease detection through longitudinal biomarker monitoring. In this interview, Bram De Moor discusses the science behind URIMON, the company’s commercialization strategy, and how RESI has supported its investor engagement. 

Bram De Moor
Founder & General Manager, You2Yourself
 CaitiCaitlin Dolegowski
Program Director, LSN

Caitlin Dolegowski (CD): For those new to You2Yourself, how would you describe URIMON and the value of longitudinal biomarker monitoring in a way that resonates with investors?

Bram De Moor (BD): URIMON is a personalized, non-invasive, urine-based liquid biopsy platform that uses urinary miRNA profiling to detect multiple serious diseases — including prostate cancer, lung cancer, and cardiovascular disease — before symptoms appear. One urine sample generates simultaneous risk scores across multiple conditions.

The longitudinal dimension is key: repeated monitoring detects biological drift months to years before clinical symptoms — the difference between catching cancer at stage I versus stage III. With no needles, no clinic visit, and at-home collection with mail-in capability, URIMON is designed for scalable, population-level adoption.

CD: What makes your approach to early disease detection fundamentally different from traditional diagnostic models?

BD: Traditional diagnostics are reactive and often focus on a single biomarker. URIMON differs in three key ways:

  • Multi-disease detection from a single sample, analyzing hundreds of miRNA species simultaneously
  • Focus on molecular signals rather than anatomical changes, enabling earlier detection
  • Use of urine as a scalable, patient-friendly biofluid that captures signals from across the body

This approach provides a unified molecular health view, reducing fragmentation across specialties.

CD: You have built a unique biobank of longitudinal samples — how does this dataset strengthen your technology and create a competitive advantage?

BD: The URIMON Biobank, developed since 2019 with over 6,500 participants under IRB-approved and GDPR-compliant protocols, is a significant strategic moat.

It enables algorithm training on longitudinal patient data, including individuals who later develop disease, supporting prospective validation. It also ensures robustness across cohorts, allowing classifiers to generalize beyond a single institution.

Replicating this dataset would require years and substantial capital, making it a durable barrier to entry.

CD: How do you think about commercialization, particularly your subscription-based model and the path toward broader reimbursement and population-level adoption?

BD: Our strategy is staged to de-risk scaling. We are entering the market under the EU IVDR Article 5(5) in-house LDT framework to accelerate time to revenue.

Our subscription model (€299–499/year) targets individuals, employer groups, and occupational health programs, aligning recurring revenue with longitudinal monitoring.

Reimbursement will follow through HTA submissions in Europe, with FDA De Novo clearance as a parallel pathway in the U.S.

CD: What key milestones or inflection points should investors be watching as you move toward your planned 2027 market entry?

BD: Key milestones include:

  • Clinical validation and publication of performance data
  • Regulatory progress under IVDR and FDA pathways
  • Launch of commercial infrastructure and first paying customers
  • Strategic partnerships and completion of financing rounds
  • These milestones will demonstrate both technical validation and commercial traction.

CD: How did participating in RESI Europe and the Innovator’s Pitch Challenge impact your investor visibility and strategic conversations?

BD: RESI provided direct access to European and transatlantic investors actively seeking early-stage diagnostic companies — a highly targeted audience that is difficult to reach through traditional outreach.

The Innovator’s Pitch Challenge offered structured validation in a competitive setting, signaling credibility to institutional investors. It also led to new investor conversations and follow-up meetings now underway.

CD: Following your recognition at RESI Europe, what are the next key priorities for You2Yourself as you move into your next phase of growth?

BD: Our focus over the next 12–18 months includes:

  • Expanding clinical evidence through continued biobank growth and prospective studies
  • Securing financing through grants and a seed-to-Series A bridge round
  • Scaling team and infrastructure across lab, regulatory, and business development functions

With favorable market conditions — including advances in NGS, growing demand for preventive health, and regulatory clarity — You2Yourself is well positioned to lead in this space.

Applications are now open for upcoming Innovator’s Pitch Challenges. Companies can apply to pitch at RESI San Diego 2026 and take the stage in front of a global network of investors and partners.

Apply to Pitch at RESI San Diego

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

The Needle Issue #25

14 Apr
Juan-Carlos-Lopez
Juan Carlos Lopez		 Andy-Marshall
Andy Marshall

The approval of multiple anti-amyloid monoclonal antibodies (mAbs) — aducanumab (Aduhelm; now withdrawn), lecanemab (Leqembi) and donanemab (Kisunla) — over the past five years has opened the era of disease-modifying Alzheimer’s drugs, albeit with only modest benefits in addressing cognitive decline (30% slowing) and associated serious safety risks, such as CNS inflammation and cerebral hemorrhages, which has limited clinical uptake. While many drug development programs target biological processes other than amyloid formation (e.g., tau and tangles, neurotransmitter receptors, neuroinflammation, autophagy, and mitochondrial or metabolic dysfunction), companies continue to optimize anti-amyloid monoclonals, but also look for alternative ways to therapeutically target Aβ.

One alternative therapeutic modality to antibodies is chimeric antigen receptor (CAR) immune cell therapy. In recent weeks, we have been thinking a lot about in vivo chimeric antigen receptor (CAR)-T therapies, which were one of the dealmaking trends in 2025, and we recommend readers check out an excellent summary of trends in the area from the consultancy firm Scitaris (you don’t even have to give them your details to download the report).

CAR-T treatments have established their clinical niche as last-ditch treatments for B-cell malignancies, with some remarkable outcomes for late-stage patients. In some cases, they have been shown to be at least twice as effective as T-cell engager bispecific antibodies in clinical studies. But they remain rather blunt instruments.

Despite advances in the clinical management of cytokine-release syndrome and immune effector cell neurotoxicity syndrome (ICANS), CAR-T treatments continue to be associated with serious risks. And while there have been advances in managing these adverse events, atypical non-ICANS neurotoxicities (NINTs) can also create serious clinical management issues, with risk factors predisposing patients to development still only poorly understood.

That said, over the past year, we have seen an increasing trend for the use of CAR-T treatments outside oncology. They have started to be applied with promising efficacy in various areas of autoimmunity (systemic lupus erythrematosus, lupus nephritis, systemic sclerosis, Sjögren’s syndrome, antisynthetase syndrome, myasthenia gravis and idiopathic inflammatory myopathies) and neuroinflammatory conditions (multiple sclerosis). In this respect, a recent paper in Science caught our attention. In it, Marco Colonna and his colleagues at Washington University in St. Louis harness astrocytes to clear amyloid plaques by promoting their ability to phagocytize Aβ.

To that end, they used in vivo gene therapy to generate astrocytes carrying chimeric antigen receptors (“CAR-As”), a strategy not unlike the one used in cancer immunotherapy. Although both macrophages (CAR-Ms) and conventional CAR-Ts have been tested in preclinical models of Alzheimer’s disease with limited success, this study reports the first attempt to directly engineer astrocytes in the body to generate CAR-As.

In broad terms, the construct used to generate CAR-As consisted of an Aβ-binding domain and the phagocytic signaling protein MEGF10 (multiple epidermal growth factor-like domains protein 10). The team examined a variety of constructs and chose two for in vivo testing. One of them combined a fragment from the Aβ-binding antibody crenezumab and MEGF10, which is primarily expressed in astrocytes. The second construct combined a fragment of aducanumab with the phagocytosis receptor Dectin-1, which is primarily expressed in microglia.

The authors packaged the constructs in an adeno-associated viral (AAV) vector under the control of an astrocyte-specific promoter and injected them intravenously into 5xFAD mice (which carry five familial Alzheimer’s disease (FAD) mutations, driving rapid Aβ plaque formation, synaptic loss, and cognitive decline starting around 2–4 months). Both CAR-As reduced amyloid burden and neuritic dystrophy, and the treatment worked both in the prophylactic and therapeutic settings.

Single-nucleus RNA sequencing and immunostaining showed that the CAR-As adopted the transcriptomic profile of activated astrocytes and readily clustered around amyloid plaques. Microglial cells, in turn, also responded to the treatment by showing a reduction of the disease-associated transcriptomic profile that is often seen after administration of monoclonal anti-Aβ antibodies. This is of interest because this disease profile of microglial cells has been suggested to contribute to the inflammatory reaction sometimes seen after Alzheimer’s immunotherapy.

A caveat of the study is that the authos saw no improvements in cognition following therapy, albeit behavioral results in mouse models have been notoriously poor at predicting outcomes in humans. However, the translational questions don’t stop there.

If in clinical practice the CAR-A approach would require an AAV vector, then immunogenicity of the treatment is going to be an issue. Pre-exposure to AAV is often a problem for gene-therapy programs, where patients are much younger. Given that Alzheimer’s is a disease associated with an elderly population, immunogenicity is likely to be exacerbated. Similarly, the delivery of 1013–1014 viral genomes to elderly patients living with Alzheimer’s—many of whom will already have a brain prone to neuroinflammation—makes the specter of unwanted side effects a major concern. In this respect, finding Alzheimer’s patients whose disease stage and age would be appropriate for a therapy with potentially highly toxic consequences for fragile recipients is also difficult to gauge.

That is not to say that CAR-immune cell therapy may not have a place in CNS disease. It just seems like neurological conditions, such as multiple sclerosis where patients are younger and potentially less fragile, are the place where much of the translational groundwork and clinical management for CAR-A or CAR-T therapies must be worked out before moving into neurodegenerative disease for elderly and cognitively compromised patients.

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Technical Risk – From Belief to Evidence 

7 Apr

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022

In the first article, The Problem Is Not the Science, Life Science Nation established that investability begins with defining a real, urgent market need. But once that foundation is clear, the next question becomes unavoidable: does the product actually work, and can that be demonstrated in a way others trust?

The next focus is technical risk, where belief must become evidence. It outlines how companies move from early signals to reproducible, credible, and translatable results—covering mechanism of action, proof of concept, reproducibility, safety, and scalability.

Once market risk is clear, the next question becomes unavoidable: does the product work, and can that be demonstrated in a way that others trust?

This is where many companies overestimate their position. Early data, promising signals, or strong academic foundations often create internal confidence. But investors are not evaluating belief; they are evaluating evidence. The distance between those two states defines technical risk.

Technical risk is not simply about whether something works once. It is about whether it works consistently, whether the mechanism is credible, and whether the results can survive the transition from controlled environments into real-world use.

The first layer of clarity comes from the mechanism of action. There must be a coherent explanation of how the biology or technology produces the intended effect. This is not a description of experimental outcomes; it is a causal story. Without it, data is difficult to interpret and harder to trust.

Proof of concept establishes that the signal exists. This can take the form of in vitro data, animal models, early human data, or a working prototype, but it must be observable and measurable. Reproducibility then determines whether that signal can be relied upon. A single experiment is not enough. Results must hold across time, cohorts, and independent attempts.

Translatability introduces another layer of complexity. What works under ideal conditions does not always work in patients, clinics, or real-world settings. Understanding how findings extend beyond the initial model is critical, particularly in biologically complex indications.

Safety, performance, and durability define the product profile. Even if effective, a product must be safe enough for its intended use, deliver a meaningful effect, and sustain that effect over time. A transient or marginal benefit rarely justifies the cost and risk of development.

Finally, manufacturability, scalability, and data integrity complete the picture. A product that cannot be produced consistently and at scale cannot become a company. Data that is poorly designed, uncontrolled, or selectively presented undermines confidence, even when the underlying science is strong.

Technical risk is resolved when the product moves from an interesting idea to something that consistently works, can be trusted, and can be translated into real-world use.

Core Elements of Technical Risk

  • Mechanism of action
  • Proof of concept
  • Reproducibility
  • Translatability
  • Safety
  • Performance and durability
  • Manufacturability and scalability
  • Data quality and integrity

Next in the series: Regulatory Risk — Navigating the Path to Approval

Tags: , , , , , , , , , , , , , , ,

The Problem Is Not the Science: A Seven-Part Series on De-Risking, Signal, and Investability 

31 Mar

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022

Early-stage life science companies do not fail because the science is weak. They fail because the science never becomes investable. Across therapeutics, devices, diagnostics, and digital health, failure rates approach ninety percent. The default explanation is technical risk. The data did not hold. The biology did not translate. The product did not perform. That is not what usually happens. What happens is structural. Companies are built without a system for converting discovery into something capital can evaluate, compare, and act on. They generate data before defining the problem. They raise capital before removing uncertainty. They move forward without knowing what the next decision-maker needs to see. Capital does not fund ideas. It funds signal.

Signal is what allows an investor or partner to act with confidence. It is produced when specific forms of uncertainty are systematically removed. Without signal, even strong science remains interesting but unfundable. With it, capital moves. Over the next six articles, we will break down how that signal is created. Not through storytelling, but through the systematic reduction of risk across a defined stack. Each layer represents a different barrier to action. Each must be addressed in sequence. Investability emerges when enough of this stack has been reduced to a level that supports a decision.

  • Market
  • Technical
  • Regulatory
  • Execution
  • Economic
  • Financing
  • Exit

The series begins where it should: with market risk. Market risk sits at the foundation. Before anything else, a real and meaningful problem must be established. It is not enough to have a promising technology. The problem must be precise, urgent, and actionable within a real system.

The clarity of the unmet need defines the problem. Urgency determines whether action is required. Identification of the buyer clarifies who decides and who pays. The current standard of care provides context for change. Differentiation defines why the product matters. Adoption friction determines how difficult implementation is. Path to payment ensures the product can be funded. If these elements are not clear, the company is not ready. It is undefined. Most companies move past this step too quickly. They begin with the science and assume the market will follow. By the time they realize it has not, they have already consumed time, capital, and credibility. When market risk is resolved, everything else begins to align. Technical work becomes purposeful. Regulatory paths become clearer. Economic value can be measured. Capital has something to anchor to. Signal begins to form.

This is where the series starts. In the articles that follow, we will move layer by layer through the stack, showing how each dimension of risk is defined, reduced, and translated into investable signal. The objective is not to simplify science. It is to make the path from discovery to capital legible and executable. The challenge in life science is not discovery.

It is the disciplined conversion of discovery into investable signal.

Market Risk

Defining Whether a Real Problem Exists

At the foundation of the De-Risk Stack is market risk. Before a founder thinks about technical validation, regulatory pathway, or fundraising strategy, there is a more basic question: does this company solve a real problem in a form the market will recognize and respond to?

This is where many early-stage life science ventures begin to drift. A founder may have compelling science, a large disease category, and years of academic work behind the technology, yet still fail to define the problem in commercial terms. Capital does not fund scientific possibilities in the abstract; it funds opportunities where a specific problem is understood, urgent, and attached to a buyer who has a reason to act.

Market risk is therefore not a question of size alone. A very large indication can still represent a weak opportunity if the unmet need is vague, the current standard of care is acceptable, or the path to payment is unclear. By contrast, a narrowly defined indication with a highly specific unmet need can be highly investable when urgency is high, the buyer is identifiable, and the product’s advantage is obvious. What matters is not breadth, but clarity.

In practice, market risk begins with the definition of unmet need. The problem must be described precisely enough that an investor, clinician, or partner can understand exactly what is broken and for whom. Urgency follows. Some conditions create pressure for action because they are life-threatening, progressive, poorly managed, or economically burdensome. Others do not. That distinction shapes adoption, tolerance for risk, and willingness to pay.

Once need and urgency are clear, attention shifts to the buyer and the system. In life science, the user, decision maker, and payer are often different actors. If you cannot identify who decides and who pays, you do not yet have a real market thesis. At the same time, every product enters an existing standard of care. You must understand how patients are currently treated, where those approaches fail, and why change is justified.

Differentiation, adoption friction, and path to payment complete the picture. A product must be better in a way that matters—not just marginally improved in a way that is difficult to notice. It must fit into real workflows, incentives, reimbursement structures, and budget constraints. If the system cannot absorb the product, market risk remains unresolved, no matter how attractive the science appears.

Market risk is resolved when a clearly defined and urgent problem exists, a real buyer is identified, the current approach is inadequate, and the product has a credible path to adoption and payment.

Core Elements of Market Risk

  • Clarity of unmet need
  • Urgency
  • Identification of the buyer
  • Current standard of care
  • Differentiation
  • Adoption friction
  • Path to payment

Market risk is the first layer of the De-Risk Stack, but it is only the beginning. Resolving whether a real, urgent problem exists establishes the foundation for everything that follows. Without it, progress elsewhere does not translate into investability.

This series examines each layer of the stack in sequence, outlining how risk is systematically reduced to convert scientific innovation into something capital can evaluate and fund.

In the next installment, the focus shifts to technical risk: how companies demonstrate that their product works, and how to de-risk the underlying technology in a way that builds investor confidence.

Check back next week for Technical Risk: De-Risking the Stack.

Tags: , , , , , , , , , , , , ,

RESI Europe 2026 Program Guide Released

17 Mar

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022

Life Science Nation (LSN) has released the official Program Guide for RESI Europe 2026, taking place March 23 in Lisbon, Portugal, followed by four days of virtual partnering on March 24–25 and March 30–31.

The hybrid conference will bring together early-stage life science and healthcare innovators with a global network of investors and strategic partners actively sourcing opportunities across drugs, devices, diagnostics, and digital health.

A central highlight of the event is the Innovator’s Pitch Challenge (IPC), where more than 20 emerging companies will present their technologies directly to investor judges and the broader RESI partnering community. These presentations offer founders the opportunity to gain visibility, receive investor feedback, and initiate conversations that can lead to future funding and strategic collaborations.

The program also features investor panels, partnering meetings, and networking opportunities designed to help founders better understand the current investment landscape and build relationships with active investors and strategic partners.

With hundreds of one-on-one partnering meetings expected to take place across the hybrid format, RESI Europe provides a focused environment for early-stage companies to connect with capital and advance their fundraising and partnership strategies.

Registration is still open, and attendees can view the full conference program in the official Program Guide.

Register for RESI Europe

Tags: , , , , , , , , , , , ,

← Older Entries